| Name | Title | Contact Details |
|---|
DUAL North America is a prominent independent underwriting organization based in the United States, part of the global DUAL Group. Established in 2013, it has become a leading program administrator in the insurance sector. The company operates under the Howden-owned DUAL Group, which is recognized as one of the largest managing general agents worldwide, with a presence in 21 countries and over $3.5 billion in gross written premium. The company specializes in expert underwriting solutions across various insurance lines, including commercial property, casualty, financial lines, and surety. DUAL North America offers more than 40 unique products tailored to meet diverse client needs. It also features a robust online platform that enables appointed producers to quote, bind policies, and manage documents digitally. With a network of over 11,000 brokers globally, DUAL North America serves a wide range of clients, from small businesses to large fleets, particularly in regions like California and Texas.
FABCON Design and Engineering (Pvt.) Ltd. is a multidisciplinary EPC Management Company, engaged in engineering, manufacturing and construction in the field of civil, mechanical, electrical and automation projects. Our primarily serving industries includes; • Oil and Gas Exploration • Refineries • Petrochemicals • OMC Plants • LPG Plants • Power Plants • Fertilizers Industry • Cement Industry • Sugar Industry • Textile Industry • Food and Beverages Industry • Paper and Pulp Industry • Commercial Infrastructure Projects • Government Infrastructure Development Sector • Defence Infrastructure Development Sector
FifthWall Solutions is a top-rated cyber insurance partner that works with 1,500+ MSPs and their clients, accessing 45+ carriers to offer the best rates and coverage options. FifthWall also educates and equips MSPs to navigate the cyber insurance process for their clients and leverage their stack along the way. Interested in partnering with FifthWall Solutions? Message us at info@fifthwallsolutions.com or call us at 844.719.0981.
Mass Bankers has been a devoted champion and supporter of Massachusetts banks since 1905. Banking has the power to change communities, one person at a time, one business at a time. By supporting our banks, we like to think we can change Massachusetts, too. Were here for banks to be there. Weve spent over a century creating resources, changing policy, and providing a common ground for banks in Massachusetts to be the best they can be. Because all of us can be better. Massachusetts banks provide support, education, and opportunity for the members of their communities. At Mass Bankers, our job is to make sure our member banks are able to do their best work. From providing educational resources to advocating for meaningful change, we make sure that banks in Massachusetts have all the tools they need to support the people around them. We support our member banks through: • Professional Development • Advocacy • Member Services • Community Website http://www.massbankers.org Phone 617-523-7595 Industry Banking Company size 11-50 employees 40 associated members Headquarters Boston, MA
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.